Immune responses associated with chronic fatigue syndrome: A case- control study

Journal of Infectious Diseases

Volumn 175, Issue 1, 1997, Pages 136-141

  Mawle, Alison C ^a   Nisenbaum, Rosane ^b   Dobbins, James G ^b   Gary Jr , Howard E ^b   Stewart, John A ^b   Reyes, Michele ^b   Steele, Lea ^b   Schmid, D Scott ^b   Reeves, William C ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE MARKER;

ADULT; AGED; ALLERGIC REACTION; ANTIGEN EXPRESSION; ARTICLE; CASE CONTROL STUDY; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; DELAYED HYPERSENSITIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNE RESPONSE; KILLER CELL; MALE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0031015337     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.1.136     Document Type: Article

References (17)

1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994;121:953-59.
2. Mawle AC, Reyes M, Schmid DS. Is chronic fatigue syndrome an infectious disease? Infect Agents Dis 1994;2:333-41.
3. Curti BD, Smith JW. Interleukin-1 in the treatment of cancer. Pharmacol Ther 1995;65:291-302.
4. Dillman RO. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother 1994;3:183-209.
5. Wadler S. The role of interferons in the treatment of solid tumors. Cancer 1992;15:949-58
6. Caligiuri M, Murray C, Buchwald D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987;139:3306-13.
7. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990;28:1404-10.
8. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis 1994;18(suppl 1):S136-41.
9. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994;(suppl 1):18:S157-9.
10. Morrison LJA, Behan WHM, Behan PO. Changes in natural killer cell phenotype in patients with post-viral fatigue syndrome. Clin Exp Immunol 1991;83:441-6.
11. Tirelli U, Marotta G, Improta S, Pinto A. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 1994;40:601-8.
12. Gupta S, Vayuvegula B. A comprehensive immunological analysis in chronic fatigue syndrome. Scand J Immunol 1991;33:319-27.
13. Lloyd A, Hickie I, Hickie C, Dwyer J, Wakefield D. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clin Exp Immunol 1992;87:76-9.
14. Straus SE, Fritz S, Dale JK, Gould B, Strober W. Lymphocyte phenotype and function in the chronic fatigue syndrome. J Clin Immunol 1993;13:30-40.
15. Chao CC, Gallagher M, Phair J, Peterson PK. Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. J Infect Dis 1990;162:1412-3.
16. Chao CC, Janoff EN, Hu S, et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 1991;3:292-8.
17. Linde A, Andersson B, Svenson SB, et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 1992;165:994-1000.